TEOSYAL® RHA2

Product Overview: TEOSYAL® RHA 2

TEOSYAL® RHA 2 is an injectable, transparent, viscoelastic gel formulated with resilient hyaluronic acid (RHA) technology. It comprises cross-linked and non-modified HA of non-animal origin, integrated with 0.3% lidocaine hydrochloride to enhance patient comfort during administration. Developed by Teoxane Laboratories (Geneva, Switzerland), RHA 2 utilizes the patented RHA process, designed to preserve the natural characteristics of hyaluronic acid chains. This allows the gel to integrate and stretch within dynamic facial tissues, aiming for a natural result even during expression.

This formulation is specifically indicated for the correction of moderate facial wrinkles and lines, such as moderate nasolabial folds, marionette lines, and glabellar lines. It provides volume and smoothing while respecting facial dynamism.

Note: This medical device is intended for use only by licensed medical professionals trained in dermal filler injection techniques.

Mechanism of Action and Properties

TEOSYAL® RHA 2 employs Resilient Hyaluronic Acid (RHA) technology, creating a cohesive HA gel structure that can adapt to tissue stress and stretch associated with facial movements. When injected into the mid-dermis, the hyaluronic acid component provides immediate volume augmentation to fill moderate wrinkles. It also attracts and retains water, contributing to localized skin hydration and improved skin texture.

The integrated 0.3% lidocaine hydrochloride acts as a local anesthetic to minimize discomfort during the injection process.

The clinical effects of TEOSYAL® RHA 2 typically persist for several months, although the exact duration is influenced by patient factors (skin type, lifestyle, age), the area treated, injection volume, and the practitioner’s technique.

Indications and Usage

TEOSYAL® RHA 2 is indicated for filling moderate facial wrinkles and lines, particularly in dynamic areas. Suitable treatment areas include:

• Moderate nasolabial folds
• Moderate marionette lines
• Glabellar lines (moderate)
• Perioral wrinkles (moderate)
• Potential use for subtle lip volume/contouring (subject to practitioner assessment and technique)

Administration should be performed via injection into the mid-dermis by qualified practitioners using appropriate techniques and adhering to aseptic standards.

Expected Outcomes

Appropriate use by a trained professional aims to achieve:

• Smoothing of moderate facial wrinkles and lines
• Restoration of subtle volume in treated areas
• Maintenance of natural facial expressions
• Improvement in skin texture and hydration locally

Potential Adverse Events

Practitioners must inform patients about potential injection-related reactions. Common, typically transient adverse events include:

• Common Reactions: Injection site redness (erythema), swelling, bruising, pain, tenderness, itching, palpable lumps or bumps. These usually resolve spontaneously within several days.
• Less Common/Rare but Serious Reactions: Persistent discoloration, firmness (induration), inflammation, infection, hypersensitivity/allergic reactions, nodule or granuloma formation, abscess, skin necrosis (tissue death, rare), vascular occlusion (rare, but serious).

Prompt recognition and management of adverse events are crucial. Patients should be instructed to report any concerning or prolonged side effects immediately.

Storage Conditions

Store the product between 2°C and 25°C. Keep away from direct sunlight and freezing temperatures. Ensure the packaging integrity before use.

Disclaimer: This information is intended as a general overview. Healthcare professionals must consult the complete guidelines accompanying TEOSYAL® RHA 2 before administration for full details on indications, contraindications, warnings, precautions, injection techniques, and potential adverse events.